Trials / Unknown
UnknownNCT05911425
Combined Treatment of Treated Bile Duct Cancer
Envolizumab in Combination With Sovalteinib for the Treatment of Treated Bile Duct Cancer in an Open, Single-arm, Phase II Clinical Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy and safety of envelizumab in combination with sovalteinib in the treatment of treated bile duct cancer, and explore treatment options to improve patient survival, while the study will attempt to explore the characteristics of the population benefiting from the treatment, and construct a preliminary efficacy prediction model by detecting markers in blood to provide a theoretical basis for implementing precise treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | envolizumab , sovalteinib | Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle. |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
- First posted
- 2023-06-22
- Last updated
- 2023-06-22
Source: ClinicalTrials.gov record NCT05911425. Inclusion in this directory is not an endorsement.